Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11035305 | 0.81 | MCL1 (0.64) | MCL1MAPK1RAB9A | |
| SCHEMBL10191381 | 0.80 | NPC1 (0.45) | NPC1RAB9AHTT | |
| SCHEMBL600072 | 0.78 | MCL1 (1.00) | MCL1MAPK1HTTCYP1A2 | |
| SCHEMBL23579159 | 0.76 | NPC1 (0.56) | NPC1RAB9AHTTKMT2A | |
| SCHEMBL29186438 | 0.76 | MCL1 (0.57) | MCL1MAPK1RAB9ACYP1A2 | |
| SCHEMBL10885557 | 0.76 | MCL1 (0.82) | MCL1MAPK1NPC1RAB9ACYP1A2 | |
| SCHEMBL1720195 | 0.76 | MCL1 (0.70) | MCL1MAPK1NPC1RAB9AHTT | |
| SCHEMBL5729067 | 0.75 | NPC1 (0.58) | NPC1RAB9AHTTKMT2A | |
| SCHEMBL6221069 | 0.75 | NPC1 (0.44) | MCL1NPC1RAB9AHTTMEN1 | |
| SCHEMBL28153265 | 0.74 | EPHX1 (0.52) | MCL1MAPK1CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569904-B1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) | 2012-01-11 | — | — | EP | disclosed |
| EP-1569904-A4 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCE (CN) | 2008-04-16 | — | — | EP | disclosed |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | LU XIAN-PING | 2008-02-28 | — | — | US | disclosed |
| US-7268157-B2 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-09-11 | — | — | US | disclosed |
| EP-1569904-A1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | Shenzhen Chipscreen Biosciences Ltd. (CN) | 2005-09-07 | — | — | EP | disclosed |
| US-20040142921-A1 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2004-07-22 | — | — | US | disclosed |
| WO-2004048333-A1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142921-A1 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | MCL1 1963/4885MAPK1 858/4885NPC1 941/4885 |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | MCL1 2361/4885MAPK1 997/4885NPC1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.